Skip to main content
. 2008 May 10;26(14):2364–2372. doi: 10.1200/JCO.2007.13.6580

Fig 3.

Fig 3.

(A, C, E, G, I) Disease-free survival and (B, D, F, H, J) overall survival. For each ErbB-2 category shown, patients are subdivided by cyclophosphamide, doxorubicin, and fluorouracil dose. (A, B) ErB-2 = 0%; (C, D) ErB-2-low/P-ErB-2-negative; (E, F) ErB-2-low/P-ErB-2-positive; (G, H) Erb-2-high/P-ErB-2-negative; (I, J) ErB-2-high/P-ErB-2-positive.